Abstract: An implantable stimulation system having a stimulation unit coupled to a programmable controller, a stimulation circuit and an array of electrodes disposed on a pair of flexible paddles is provided for selectively stimulating at least one pelvic (e.g., cavernous) nerve. The programmable controller is pre-programmed to run an excitation electrode routine that selectively scans the electrode arrays with a series of directional current flows to optimize electrode selection for use in stimulating a nerve. The implantable stimulation system may be programmed to run a first stimulation pulse sequence corresponding to a first mode for invoking a rapid erectile response, a second nerve rehabilitation stimulation mode for rehabilitating neural transmission in a cavernous nerve, a third penile rehabilitation mode for reducing penile fibrosis, and/or a fourth bladder nerve rehabilitation mode for rehabilitating neural transmission in nerves that control the lower urinary tract.

Abstract: Systems and methods for monitoring penile tumescence are provided that overcome the drawbacks of previously known systems by providing a wearable formed of a flexible and elastic tube having a plurality of sensors disposed on or embedded within it, the wearable configured to be applied to a penis of a subject, and a spaced-apart controller operatively coupled to retrieve data regarding circumferential and axial dimensional changes and penile rigidity from the plurality of sensors and transmit that data to an external computer or smartphone for analysis and display. The plurality of sensors may be coupled to the spaced-apart controller via a flexible lead or wirelessly using a passive RFID system.

Abstract: An implantable stimulation system having an implantable stimulation unit coupled to a programmable controller, a stimulation circuit and an array of electrodes disposed on a pair of flexible paddles is provided for selectively stimulating at least one cavernous nerve. The programmable controller is pre-programmed to run an excitation electrode routine that selectively scans the electrode arrays on the paddles with a series of directional current flows, in at least two directions and within at least two regions, to optimize electrode selection for use in stimulating the cavernous nerve. The implantable stimulation system may be programmed to run a first stimulation pulse sequence corresponding to a first mode for invoking a rapid erectile response, and optionally, a second nerve rehabilitation stimulation mode selected to rehabilitate neural transmission in a cavernous nerve, and/or a third penile rehabilitation mode selected to reduce penile fibrosis. Methods of operating the system also are provided.

Abstract: An implantable stimulation system having an implantable stimulation unit coupled to a programmable controller, a stimulation circuit and an array of electrodes disposed on a pair of flexible paddles is provided for selectively stimulating at least one cavernous nerve. The programmable controller is pre-programmed to run an excitation electrode routine that selectively scans the electrode arrays on the paddles with a series of directional current flows, in at least two directions and within at least two regions, to optimize electrode selection for use in stimulating the cavernous nerve. The implantable stimulation system may be programmed to run a first stimulation pulse sequence corresponding to a first mode for invoking a rapid erectile response, and optionally, a second nerve rehabilitation stimulation mode selected to rehabilitate neural transmission in a cavernous nerve, and/or a third penile rehabilitation mode selected to reduce penile fibrosis. Methods of operating the system also are provided.

Abstract: The present invention is related to the peptide Des-[Asp1]-[Ala1]-Angiotensin-(1-7) (Ala1-Arg2-Val3-Tyr4-Ile5-His6-Pro7) (SEQ ID NO: 1) and/or its related compounds as vasodilating and cardioprotective agents to be used in mammals. This invention also comprises the production of compounds containing Des-[Asp1]-[Ala1]-Angiotensin-(1-7) and/or its related compounds and its use in methods for treating and preventing diseases.

Abstract: Systems and methods are provided for treating a sexual disorder such as erectile dysfunction (ED) or female sexual arousal disorder (FSAD). An electrical stimulation system may include an implantable stimulation unit, an external patient controller, and an external physician controller. The implantable stimulation unit has an array of electrodes disposed on one or more flexible substrates configured to conform to a patient's anatomy at the pelvic plexus. Post-implantation, the physician controller may direct the stimulation unit to stimulate with select electrode(s) of the array to determine which electrode configuration provides optimal sexual arousal. The patient controller may be used to cause the stimulation unit to stimulate using the optimal electrode configuration at desired times.

Abstract: Systems and methods are provided for treating a sexual disorder such as erectile dysfunction (ED) or female sexual arousal disorder (FSAD). An electrical stimulation system may include an implantable stimulation unit, an external patient controller, and an external physician controller. The implantable stimulation unit has an array of electrodes disposed on one or more flexible substrates configured to conform to a patient's anatomy at the pelvic plexus. Post-implantation, the physician controller may direct the stimulation unit to stimulate with select electrode(s) of the array to determine which electrode configuration provides optimal sexual arousal. The patient controller may be used to cause the stimulation unit to stimulate using the optimal electrode configuration at desired times.

Abstract: Systems and methods are provided for treating a sexual disorder such as erectile dysfunction (ED) or female sexual arousal disorder (FSAD). An electrical stimulation system may include an implantable stimulation unit, an external patient controller, and an external physician controller. The implantable stimulation unit has an array of electrodes disposed on one or more flexible substrates configured to conform to a patient's anatomy at the pelvic plexus. Post-implantation, the physician controller may direct the stimulation unit to stimulate with select electrode(s) of the array to determine which electrode configuration provides optimal sexual arousal. The patient controller may be used to cause the stimulation unit to stimulate using the optimal electrode configuration at desired times.

Abstract: The present invention discloses formulations for the treatment and prevention of alopecia; the formulations comprise angiotensin-(1-7) and/or their analogues, encapsulated in ultradeformable vesicles prepared from specific combinations of phospholipids and surfactants, which confer efficacy to topical application in the control of hair growth, which indicates their great potential for the prevention and treatment of alopecia. The invention also describes formulations containing A779 Mas receptor antagonist of angiotensin-(1-7) and/or their analogues and their use in inhibiting hair growth.

Abstract: The present invention relates to the use of Ang-(1-7) and/or Ang-(1-7) receptor agonist and/or Ang (1-7) analogue in treating/restoring erectile dysfunction.

Abstract: The present invention is related to the peptide Des-[Asp1]-[Ala1]-Angiotensin-(1-7) (Ala1-Arg2-Val3-Tyr4-Ile5-His6-Pro7) and/or its related compounds as vasodilating and cardioprotective agents to be used in mammals. This invention also comprises the production of compositions containing Des-[Asp1]-[Ala1]-Angiotensin-(1-7) and/or its related compounds and its use in methods for treating and preventing diseases.

Abstract: The present invention relates to the use of Ang-(1-7) and/or Ang-(1-7) receptor agonist and/or Ang (1-7) analogue in treating/restoring erectile dysfunction.